期刊
BMJ OPEN
卷 12, 期 3, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-055214
关键词
general diabetes; preventive medicine; diabetes & endocrinology
资金
- Health Research Council of New Zealand
- Ministry of Health New Zealand
- Healthier Lives National Science Challenge [16/724]
This study found no evidence of clinical benefit from the supplementation with Lactobacillus rhamnosus HN001 and/or cereal enriched with oat-derived beta-glucan (OBG) on HbA(1c) and all secondary outcomes relevant to adults with pre-diabetes.
Aims To evaluate the effect of the probiotic Lactobacillus rhamnosus HN001 and/or cereal enriched with oat-derived beta-glucan (OBG) on metabolic and mental health outcomes when administered to adults with pre-diabetes. Design 2x2 factorial design randomised, parallel-groups placebo-controlled; double-blinded for probiotic, single-blinded for cereals. Participants Community-dwelling adults aged 18-80 years with pre-diabetes: glycated haemoglobin (HbA(1c)) 41-49 mmol/mol. Interventions Capsules containing Lactobacillus rhamnosus (HN001) (6x10(9) colony-forming units/day), or placebo capsules; and cereal containing 4 g/day OBG or calorie-matched control cereal, taken daily, for 6 months. Study groups were: (A) HN001 capsules+OBG cereal; (B) HN001 capsules+control cereal; (C) placebo capsules+OBG cereal and (D) placebo capsules+control cereal. Outcome measures Primary outcome: HbA(1c) at 6 months. Secondary outcomes: fasting plasma glucose, fasting insulin, homeostatic model assessment of insulin resistance, fasting lipids, blood pressure, body weight, waist circumference, body mass index and mental well-being. Results 153 participants were randomised. There was complete HbA(1c) outcome data available for 129 participants. At 6 months the mean (SD) HbA(1c) was 45.9 (4.4) mmol/mol, n=66 for HN001, and 46.7 (4.3) mmol/mol, n=63 for placebo capsules; 46.5 (4.0) mmol/mol, n=67 for OBG and 46.0 (4.6) mmol/mol n=62 for control cereal. The estimated difference between HN001-placebo capsules was -0.83, 95% CI -1.93 to 0.27 mmol/mol, p=0.63, and between OBG-control cereals -0.17, 95% CI -1.28 to 0.94 mmol/mol, p=0.76. There was no significant interaction between treatments p=0.79. There were no differences between groups or significant interactions between treatments for any of the secondary outcomes. Conclusions This study found no evidence of clinical benefit from the supplementation with either HN001 and/or cereal containing 4 g OBG on HbA(1c) and all secondary outcomes relevant to adults with pre-diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据